– FDA has issued a clinical hold on initial IND submission required to initiate Phase 2b trial of LSD for the treatment of generalized anxiety disorder – NEW YORK, Dec. 21, 2021 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-inspired therapies, today announced that the U.S.


Previous articlePT278 – Ayize Jama-Everett, Courtney Watson, Leticia Brown, and Kufikiri Imara – A Table of Our Own
Next articlehttps://www.globenewswire.com/news-release/2021/12/21/2355961/0/en/PharmaTher-Provides-Update-on-Product-Pipeline-and-Expected-Milestones-for-2022.html